As of Apr 17
| +0.12 / +0.70%|
The 4 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 31.50, with a high estimate of 41.00 and a low estimate of 25.00. The median estimate represents a +82.08% increase from the last price of 17.30.
The current consensus among 5 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.